Drug
Inebilizumab clinical trials
Also written MEDI-551 and UPLIZNA.
- studies test it
- 23
- open now
- 11
- in phase 3
- 6
- first study started
- 2010
Keep track of what changes. Save the inebilizumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
23 studies that test it; most in 2026 (6)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 3 |
| 2015 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 11
- Phase 3
- 6
- Phase 4
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 18 · Other 5
Amgen (10) · MedImmune LLC (5) · Tanabe Pharma Corporation (1) · AstraZeneca (1) · Charite University, Berlin, Germany (1) · Hansoh BioMedical R&D Company (1) · Ruijin Hospital (1) · Massachusetts General Hospital (1)
Often tested with
Tested in the same studies.
Blinatumomab (1) · Eculizumab (1) · Ravulizumab (1) · Satralizumab (1) · Dazodalibep (1)
Studies
Open first, then newest update. How each study uses inebilizumab is read from its arms, and is right about nine times in ten.
Testing it · 23
- A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)RecruitingPhase 2AmgenNCT06987539Written as Inebilizumab
- A Trial of Inebilizumab in Participants With Autoimmune HepatitisRecruitingPhase 3AmgenNCT07598825Written as Inebilizumab
- Inebilizumab for the Treatment of Patients With Type 1 Autoimmune PancreatitisRecruitingPhase 4Ruijin HospitalNCT07862075Written as Inebilizumab
- A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune DiseasesRecruitingPhase 2AmgenNCT06570798Written as Inebilizumab
- A Phase 3 Study of Inebilizumab in Participants With Primary Membranous NephropathyRecruitingPhase 3AmgenNCT07851220Written as Inebilizumab
- Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSDRecruitingPhase 4Massachusetts General HospitalNCT07010302Written as Inebilizumab
- Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RDNot yet recruitingPhase 2AmgenNCT07222553Written as Inebilizumab
- CD19-B Cell Depletion in PAIS-ME/CFS PatientsNot yet recruitingPhase 2Charite University, Berlin, GermanyNCT07724834Written as Inebilizumab
- Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum DisorderRecruitingPhase 2AmgenNCT05549258Written as Inebilizumab
- The ExTINGUISH Trial of Inebilizumab in NMDAR EncephalitisRecruitingPhase 2University of UtahNCT04372615Written as Inebilizumab
- A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum DisordersNot yet recruitingPhase 4Hansoh BioMedical R&D CompanyNCT06212245Written as Inebilizumab
- Myasthenia Gravis Inebilizumab TrialActive, not recruitingPhase 3AmgenNCT04524273Written as inebilizumab
- A Study of Inebilizumab Efficacy and Safety in IgG4- Related DiseaseActive, not recruitingPhase 3AmgenNCT04540497Written as Inebilizumab
- A Study of MT-0551 in Patients With Systemic SclerosisActive, not recruitingPhase 3Tanabe Pharma CorporationNCT05198557Written as Inebilizumab
- Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)Active, not recruitingPhase 4AmgenNCT06180278Written as Inebilizumab
- Safety and Tolerability of Inebilizumab, VIB4920, or the Combination in Highly Sensitized Candidates Awaiting Kidney Transplantation From a Deceased DonorWithdrawnPhase 2AmgenNCT04174677Written as Inebilizumab
- N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum DisordersCompletedPhase 2/3MedImmune LLCNCT02200770Written as Inebilizumab
- MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Multiple MyelomaTerminatedPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT03218163Written as MEDI-551 Maintenance
- Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple SclerosisCompletedPhase 1MedImmune LLCNCT01585766Written as MEDI-551 30 MG-IV
- A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)CompletedPhase 2MedImmune LLCNCT01453205Written as MEDI-551 2 mg/kg
See all 23 studies that test inebilizumab →
Given in every arm · 2 — inebilizumab is usual care beside what is tested
- A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell MalignanciesCompletedPhase 1/2MedImmune LLCNCT00983619Written as MEDI-551
- Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell LymphomasCompletedPhase 1/2MedImmune LLCNCT02271945Written as MEDI-551 12 mg/kg
Codes
What other systems call inebilizumab · ClinicalTrials.gg INT000514
- MeSH (NLM) C000609745inebilizumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 74T7185BMMINEBILIZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 2373951One source FDA
- Wikidata Q25326696InebilizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C88283InebilizumabOne source FDA
- DrugBank DB12530One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000609745 | inebilizumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 74T7185BMM | INEBILIZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2373951 | — | One source FDA |
| Wikidata | Q25326696 | Inebilizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C88283 | Inebilizumab | One source FDA |
| DrugBank | DB12530 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.